Experimental drug IC14 targets heart inflammation in rare disease
Disease control
Completed
This early-phase trial tested a drug called IC14 in one person with arrhythmogenic cardiomyopathy, a rare heart condition that can cause dangerous heart rhythms. The goal was to see if the drug is safe and reduces inflammation, using blood tests and heart monitoring. The study di…
Phase: PHASE1, PHASE2 • Sponsor: Implicit Bioscience • Aim: Disease control
Last updated May 07, 2026 18:41 UTC